BioCryst Pharmaceuticals
BCRX
BCRX
116 hedge funds and large institutions have $764M invested in BioCryst Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 26 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
28% more call options, than puts
Call options by funds: $1.86M | Put options by funds: $1.46M
13% more funds holding
Funds holding: 103 → 116 (+13)
3.02% more ownership
Funds ownership: 88.53% → 91.56% (+3%)
Holders
116
Holding in Top 10
4
Calls
$1.86M
Puts
$1.46M
Top Buyers
| 1 | +$17.2M | |
| 2 | +$8.8M | |
| 3 | +$8.32M | |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$7.99M |
| 5 |
BlackRock
New York
|
+$7.74M |
Top Sellers
| 1 | -$5.07M | |
| 2 | -$3.93M | |
| 3 | -$2.15M | |
| 4 |
Renaissance Technologies
New York
|
-$1.35M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$780K |